These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 39039670)

  • 1. Circumventing Cardiovascular Calamities: The Dawn of ANGPTL3 Blockade in Severe Dyslipidemia Management.
    Namitokov A; Karabakhtsieva K
    Cardiovasc Hematol Disord Drug Targets; 2024; 24(2):59-64. PubMed ID: 39039670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiopoietin-Like Protein 3 (ANGPTL3) Modulates Lipoprotein Metabolism and Dyslipidemia.
    Chen PY; Gao WY; Liou JW; Lin CY; Wu MJ; Yen JH
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34298929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: New therapeutic approaches for the treatment of atherogenic dyslipidemia.
    Ruscica M; Zimetti F; Adorni MP; Sirtori CR; Lupo MG; Ferri N
    Pharmacol Res; 2020 Mar; 153():104653. PubMed ID: 31931117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ANGPTL3 inhibition, dyslipidemia, and cardiovascular diseases.
    Luo F; Das A; Khetarpal SA; Fang Z; Zelniker TA; Rosenson RS; Qamar A
    Trends Cardiovasc Med; 2024 May; 34(4):215-222. PubMed ID: 36746257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiopoietin-Like Protein 3 (ANGPTL3) Inhibitors in the Management of Refractory Hypercholesterolemia.
    Kosmas CE; Bousvarou MD; Sourlas A; Papakonstantinou EJ; Peña Genao E; Echavarria Uceta R; Guzman E
    Clin Pharmacol; 2022; 14():49-59. PubMed ID: 35873366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets.
    Akoumianakis I; Zvintzou E; Kypreos K; Filippatos TD
    Curr Atheroscler Rep; 2021 Mar; 23(5):20. PubMed ID: 33694000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting angiopoietin-like 3 in atherosclerosis: From bench to bedside.
    Ling P; Zheng X; Luo S; Ge J; Xu S; Weng J
    Diabetes Obes Metab; 2021 Sep; 23(9):2020-2034. PubMed ID: 34047441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ANGPTL3 as a Drug Target in Hyperlipidemia and Atherosclerosis.
    Mohamed F; Mansfield BS; Raal FJ
    Curr Atheroscler Rep; 2022 Dec; 24(12):959-967. PubMed ID: 36367663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evinacumab to treat hypercholesterolemia.
    Engler C; Ebenbichler C
    Drugs Today (Barc); 2021 Oct; 57(10):607-619. PubMed ID: 34713869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New insights into ANGPLT3 in controlling lipoprotein metabolism and risk of cardiovascular diseases.
    Su X; Peng DQ
    Lipids Health Dis; 2018 Jan; 17(1):12. PubMed ID: 29334984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New Therapeutic Approaches to the Treatment of Dyslipidemia 1: ApoC-III and ANGPTL3.
    Kim JY; Kim NH
    J Lipid Atheroscler; 2023 Jan; 12(1):23-36. PubMed ID: 36761060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ANGPTL3 as therapeutic target.
    Kersten S
    Curr Opin Lipidol; 2021 Dec; 32(6):335-341. PubMed ID: 34581310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiopoietin-Like 3 (ANGPTL3) and Atherosclerosis: Lipid and Non-Lipid Related Effects.
    Lupo MG; Ferri N
    J Cardiovasc Dev Dis; 2018 Jul; 5(3):. PubMed ID: 30011918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcriptomic therapy for dyslipidemias utilizing nucleic acids targeted at ANGPTL3.
    Watts GF; Raal FJ; Chan DC
    Future Cardiol; 2022 Feb; 18(2):143-153. PubMed ID: 34651521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiopoietin-like 3: An important protein in regulating lipoprotein levels.
    Burks KH; Basu D; Goldberg IJ; Stitziel NO
    Best Pract Res Clin Endocrinol Metab; 2023 May; 37(3):101688. PubMed ID: 35999139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiopoietin-like 3 in lipoprotein metabolism.
    Kersten S
    Nat Rev Endocrinol; 2017 Dec; 13(12):731-739. PubMed ID: 28984319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Lipid-Modulating Effect of Tangeretin on the Inhibition of Angiopoietin-like 3 (ANGPTL3) Gene Expression through Regulation of LXRα Activation in Hepatic Cells.
    Chen PY; Chao TY; Hsu HJ; Wang CY; Lin CY; Gao WY; Wu MJ; Yen JH
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiopoietin-Like 3 Protein Inhibition: A New Frontier in Lipid-Lowering Treatment.
    Lang W; Frishman WH
    Cardiol Rev; 2019; 27(4):211-217. PubMed ID: 31008773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiopoietin-like proteins inhibitors: New horizons in the treatment of atherogenic dyslipidemia and familial hypercholesterolemia.
    Surma S; Romańczyk M; Filipiak KJ
    Cardiol J; 2023; 30(1):131-142. PubMed ID: 33470417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiopoietin-like 3 inhibition of endothelial lipase is not modulated by angiopoietin-like 8.
    Sylvers-Davie KL; Segura-Roman A; Salvi AM; Schache KJ; Davies BSJ
    J Lipid Res; 2021; 62():100112. PubMed ID: 34461133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.